JPWO2021188685A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021188685A5 JPWO2021188685A5 JP2022556254A JP2022556254A JPWO2021188685A5 JP WO2021188685 A5 JPWO2021188685 A5 JP WO2021188685A5 JP 2022556254 A JP2022556254 A JP 2022556254A JP 2022556254 A JP2022556254 A JP 2022556254A JP WO2021188685 A5 JPWO2021188685 A5 JP WO2021188685A5
- Authority
- JP
- Japan
- Prior art keywords
- embolic composition
- pharmaceutical
- therapeutic agent
- embolic
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003073 embolic effect Effects 0.000 claims 21
- 239000003814 drug Substances 0.000 claims 13
- 239000008177 pharmaceutical agent Substances 0.000 claims 13
- 229940124597 therapeutic agent Drugs 0.000 claims 13
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 229920000249 biocompatible polymer Polymers 0.000 claims 3
- 239000000178 monomer Substances 0.000 claims 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
- 229960005243 carmustine Drugs 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 238000010828 elution Methods 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229960003787 sorafenib Drugs 0.000 claims 2
- 229960001796 sunitinib Drugs 0.000 claims 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229960004964 temozolomide Drugs 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- 238000012800 visualization Methods 0.000 claims 1
Claims (20)
医薬品または治療剤を含有する非生理学的溶液と、
を含み、
前記実質的に安定な生体適合性ポリマーは、前記非生理学的溶液には可溶性であり、生理学的溶液には不溶性である、
塞栓組成物。 a first monomer comprising a polymerizable moiety having a biodegradable or biostable bond to a visualization agent having at least one aromatic ring comprising at least one iodine atom; and a second monomer comprising a polymerizable moiety and at least one hydroxyl group. a substantially stable biocompatible polymer comprising a reaction product of the monomer;
a non-physiological solution containing a pharmaceutical or therapeutic agent;
including;
the substantially stable biocompatible polymer is soluble in the non-physiological solution and insoluble in the physiological solution;
Embolic composition.
請求項１に記載の塞栓組成物。 at least one of the at least one iodine atom is a radioactive isotope;
The embolic composition of claim 1.
請求項２に記載の塞栓組成物。 the radioisotope is 123 I, 124 I, 125 I, 131 I, or a combination thereof;
3. The embolic composition of claim 2.
請求項１に記載の塞栓組成物。 the pharmaceutical or therapeutic agent is doxorubicin, irinotecan, sunitinib, sorafenib, paclitaxel, temozolomide, oxaliplatin, gemcitabine, carmustine, cyclophosphamide, vincristine, an antibody, or a combination thereof;
The embolic composition of claim 1.
請求項１に記載の塞栓組成物。 the pharmaceutical or therapeutic agent is paclitaxel;
The embolic composition of claim 1.
請求項１に記載の塞栓組成物。 the pharmaceutical or therapeutic agent is irinotecan;
The embolic composition of claim 1.
請求項１に記載の塞栓組成物。 the pharmaceutical or therapeutic agent is doxorubicin;
The embolic composition of claim 1.
請求項１に記載の塞栓組成物。 the pharmaceutical or therapeutic agent is sunitinib;
The embolic composition of claim 1.
請求項１に記載の塞栓組成物。 the pharmaceutical or therapeutic agent is sorafenib;
The embolic composition of claim 1.
請求項１に記載の塞栓組成物。 the pharmaceutical or therapeutic agent is gemcitabine;
The embolic composition of claim 1.
請求項１に記載の塞栓組成物。 the pharmaceutical or therapeutic agent is oxaliplatin;
The embolic composition of claim 1.
請求項１に記載の塞栓組成物。 the pharmaceutical or therapeutic agent is cyclophosphamide;
The embolic composition of claim 1.
請求項１に記載の塞栓組成物。 the pharmaceutical or therapeutic agent is temozolomide;
The embolic composition of claim 1.
請求項１に記載の塞栓組成物。 the pharmaceutical or therapeutic agent is carmustine;
The embolic composition of claim 1.
前記治療部位に存在する状態を治療することと、
を含む、治療方法のための、
請求項１に記載の塞栓組成物。 delivering the embolic composition to a treatment site;
treating a condition present at the treatment site;
for treatment methods, including;
The embolic composition of claim 1 .
請求項１５に記載の塞栓組成物。 said delivery results in precipitation of said substantially stable biocompatible polymer in said physiological solution;
16. The embolic composition of claim 15.
請求項１５に記載の塞栓組成物。 the treatment site is within the lumen;
16. The embolic composition of claim 15.
請求項１５に記載の塞栓組成物。 the condition is cancer, tumor, unwanted growth, tissue proliferation, or a combination thereof;
16. The embolic composition of claim 15.
請求項１５に記載の塞栓組成物。 The delivery results in elution of the pharmaceutical or therapeutic agent.
The embolic composition of claim 15.
請求項１９に記載の塞栓組成物。 the elution is logarithmic;
20. The embolic composition of claim 19.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062990812P | 2020-03-17 | 2020-03-17 | |
| US62/990,812 | 2020-03-17 | ||
| PCT/US2021/022783 WO2021188685A1 (en) | 2020-03-17 | 2021-03-17 | Liquid embolics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518271A JP2023518271A (en) | 2023-04-28 |
| JPWO2021188685A5 true JPWO2021188685A5 (en) | 2024-03-27 |
Family
ID=77747181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556254A Pending JP2023518271A (en) | 2020-03-17 | 2021-03-17 | liquid embolic agent |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210290816A1 (en) |
| EP (1) | EP4121130A4 (en) |
| JP (1) | JP2023518271A (en) |
| KR (1) | KR20220156862A (en) |
| CN (1) | CN115279427A (en) |
| WO (1) | WO2021188685A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2861257B1 (en) | 2012-06-14 | 2021-12-08 | Microvention, Inc. | Polymeric treatment compositions |
| US10368874B2 (en) | 2016-08-26 | 2019-08-06 | Microvention, Inc. | Embolic compositions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2621597C (en) * | 2005-09-21 | 2014-06-10 | Surmodics, Inc. | In vivo formed matrices including natural biodegradable polysaccharides and ophthalmic uses thereof |
| CL2007002878A1 (en) * | 2006-10-06 | 2008-08-01 | Takeda Pharmaceutical | PHARMACEUTICAL AGENT UNDERSTANDING 1) AN HER2 INHIBITOR THAT HAS A PIRROLOPIRIMIDINE OR PIRAZOLOPIRIMIDINE SKELETON AND 2) A HORMONAL OR ANTI-BANK THERAPEUTIC AGENT IN COMBINATION; AND USE FOR THE PREVENTION OR TREATMENT OF CANCER. |
| US20080107744A1 (en) * | 2006-11-06 | 2008-05-08 | Jack Fa-De Chu | Injectable hollow tissue filler |
| WO2009038922A1 (en) * | 2007-08-21 | 2009-03-26 | Boston Scientific Limited | Forming embolic particles |
| CN101513542B (en) * | 2009-03-27 | 2012-08-15 | 山东大正医疗器械股份有限公司 | Method for preparing iodic liquid embolic agent capable of self-developing for long-time |
| WO2011076941A1 (en) * | 2009-12-23 | 2011-06-30 | Magna Steyr Fahrzeugtechnik Ag & Co Kg | Accumulator with voltage-generating cells and a cruciform, l-shaped or t-shaped intermediate element arranged between said cells |
| EP2365009A1 (en) * | 2010-03-10 | 2011-09-14 | Universite Claude Bernard Lyon 1 (UCBL) | Radiopaque, non-biodegradable, water-insoluble iodinated benzyl ethers of poly(vinyl alcohol), preparation method thereof, injectable embolizing compositions containing thereof and use thereof |
| EP2861257B1 (en) * | 2012-06-14 | 2021-12-08 | Microvention, Inc. | Polymeric treatment compositions |
| EP2968165B1 (en) * | 2013-03-13 | 2023-09-13 | Biosphere Medical, Inc. | Compositions and associated methods for radioisotope-binding microparticles |
| CN103315945B (en) * | 2013-06-21 | 2014-12-24 | 清华大学 | Vascular embolic agent as well as injection device and application thereof |
| GB2521997A (en) * | 2013-09-06 | 2015-07-15 | Biocompatibles Uk Ltd | Radiopaque polymers |
| GB2519738A (en) * | 2013-09-06 | 2015-05-06 | Biocompatibles Uk Ltd | Radiopaque polymers |
| US20150290344A1 (en) * | 2014-04-11 | 2015-10-15 | Clemson University | Biodegradable polyester- and poly(ester amide) based x-ray imaging agents |
| US10368874B2 (en) * | 2016-08-26 | 2019-08-06 | Microvention, Inc. | Embolic compositions |
| WO2019074965A1 (en) * | 2017-10-09 | 2019-04-18 | Microvention, Inc. | Radioactive liquid embolic |
-
2021
- 2021-03-17 WO PCT/US2021/022783 patent/WO2021188685A1/en unknown
- 2021-03-17 US US17/204,581 patent/US20210290816A1/en active Pending
- 2021-03-17 EP EP21771760.2A patent/EP4121130A4/en active Pending
- 2021-03-17 JP JP2022556254A patent/JP2023518271A/en active Pending
- 2021-03-17 CN CN202180021654.0A patent/CN115279427A/en active Pending
- 2021-03-17 KR KR1020227035657A patent/KR20220156862A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4416942B2 (en) | Radioembolic composition | |
| US20240139096A1 (en) | Radiation sensitizer of anti-cancer chemotherapy sensitizer | |
| CN101365447A (en) | Pharmaceuticals compositions containing nanomaterials useful for treating restenotic lesions | |
| JP2001521911A5 (en) | ||
| JP2012520297A (en) | Products and methods for the treatment of vascular diseases | |
| US20130266508A1 (en) | Thermosensitive hydrogel for coating radioisotope and chemotherapeutic agent to treat cancer and method for preparing the same | |
| JP2009513696A (en) | Biodegradable complex for internal local radiation therapy | |
| US20200030238A1 (en) | Microspheres containing therapeutic agents and related methods of use | |
| JP2017503846A (en) | Neoplasmic treatment | |
| JP2023518271A (en) | liquid embolic agent | |
| WO2021189052A1 (en) | Composition for radiation treatment of intracavitary or metastatic deposits of malignancy and method for treatment therewith | |
| JPWO2021188685A5 (en) | ||
| CN110167602A (en) | Chemoembolization emulsion compositions and preparation method thereof | |
| WO2019035975A1 (en) | Microspheres containing therapeutic agents and related methods of use | |
| JP6339062B2 (en) | Radiation / chemotherapy sensitizer for intratumoral injection that releases hydrogen peroxide slowly using hydrogel as carrier | |
| CN116650681A (en) | Radioactive embolism microsphere with secondary targeting capability, preparation method and application thereof | |
| CZ2017634A3 (en) | Supramolecular complex of platinum metallo-complex oxycellulose matrix with gradual release of platinum metal complex and its use | |
| CZ307237B6 (en) | A supramolecular complex of an oxycellulose matrix with a taxol derivative with sequential release of the taxol derivative and its use | |
| CZ2016802A3 (en) | A supramolecular complex of an oxycellulose matrix with an anthracycline cytostatic with sequential release of an anthracycline cytostatic and its use | |
| JP2009517356A5 (en) | ||
| TW201317005A (en) | Temperature-sensitive hydrogel that encloses radioisotopes and chemotherapeutic agent for application in cancer treatment and manufacturing method thereof |